Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway

Cardiology

Volumn 115, Issue 3, 2010, Pages 221-228

  Zhou, Guangyi ^a   Ge, Song ^a   Liu, Dezhi ^a   Xu, Gelin ^a   Zhang, Renliang ^a   Yin, Qin ^a   Zhu, Wusheng ^a   Chen, Jieli ^b   Liu, Xinfeng ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

5 Lipoxygenase activating protein; Atherosclerosis; Atorvastatin

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; LEUKOTRIENE D4; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BALLOON DILATATION; CAROTID ARTERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOLOGY; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CAROTID STENOSIS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ELASTIC TISSUE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEPTANOIC ACIDS; LEUKOTRIENE D4; LIPIDS; LIPOXINS; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PYRROLES; RABBITS; RECEPTORS, LEUKOTRIENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUNICA INTIMA;

EID: 77949459403     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296017     Document Type: Article

References (34)

1. Henderson RD, Eliasziw M, Fox AJ, Rothwell PM, Barnett HJ: Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Stroke 2000; 31: 128-132. (Pubitemid 30035764)
2. Rubba P: Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007; 67(Suppl 1):17-27.
3. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-239. (Pubitemid 38282747)
4. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
5. Ge S, Zhou G, Cheng S, Liu D, Xu J, Xu G, Liu X: Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 2009; 205: 74-79.
6. Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT: Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter casecontrol study. Ann Hum Genet 2007; 71: 620-629. (Pubitemid 47087070)
7. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, Pasdar A, Grant SF, Whalley LJ, Hakonarson H, Thorsteinsdottir U, Kong A, Gulcher J, Stefansson K, MacLeod MJ: Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-509. (Pubitemid 40250529)
8. Muller DW, Ellis SG, Topol EJ: Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992; 19: 418-432.
9. Chen SJ, Li H, Durand J, Oparil S, Chen YF: Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996; 93: 577-584. (Pubitemid 26043619)
10. The Guide for the Care and Use of Laboratory Animals, NIH Publication No. 85-123, revised. Bethesda, US National Institutes of Health, 1996.
11. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118. (Pubitemid 40261799)
12. Weiss D, Sorescu D, Taylor WR: Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87: 25C-32C. (Pubitemid 32385759)
13. Saijonmaa O, Nyman T, Fyhrquist F: Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. Am J Physiol Heart Circ Physiol 2007; 292:H1917-H1921. (Pubitemid 46572416)
14. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
15. Ray KK, Cannon CP, Ganz P: Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006; 98: 18P-25P. (Pubitemid 44779497)
16. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20: 189-197. (Pubitemid 30048363)
17. Tanimoto A, Murata Y, Wang KY, Tsutsui M, Kohno K, Sasaguri Y: Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem 2008; 283: 4643-4651.
18. Shiraya S, Miyake T, Aoki M, Yoshikazu F, Ohgi S, Nishimura M, Ogihara T, Morishita R: Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009; 202: 34-40.
19. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ: Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NFkappaB-and AP-1-mediated matrix metalloproteinase-expression and is inhibited by atorvastatin. J Biol Chem 2006; 281: 15099-15109. (Pubitemid 43855099)
20. Martínez-Sales V, Vila V, Ferrando M, Reganon E: Atorvastatin neutralizes the up-regulation of thrombospondin-1 induced by thrombin in human umbilical vein endothelial cells. Endothelium 2007; 14: 233-238. (Pubitemid 47543009)
21. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Böhm M, Laufs U: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-1574. (Pubitemid 37187782)
22. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 1452-1458.
23. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243. (Pubitemid 36183986)
24. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, Spigonardo F, Bucci M, Cuccurullo F, Prescott SM, Stafforini DM: Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005; 25: 1665-1670. (Pubitemid 41098938)
25. Bäck M, Sultan A, Ovchinnikova O, Hansson GK: 5-lipoxygenase- activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007; 100: 946-949. (Pubitemid 46598919)
26. Woszczek G, Chen LY, Nagineni S, Shelhamer JH: IL-10 inhibits cysteinyl leukotrieneinduced activation of human monocytes and monocyte-derived dendritic cells. J Immunol 2008; 180: 7597-7603.
27. Osher E, Weisinger G, Limor R, Tordjman K, Stern N: The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol 2006; 252: 201-206. (Pubitemid 43914099)
28. Gómez-Hernández A, Sánchez-Galán E, Ortego M, Martín-Ventura JL, Blanco-Co lio LM, Tarín-Vicente N, Jiménez-Nacher JJ, López-Bescos L, Egido J, Tuñón J: Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 2008; 102: 12-18.
29. Seres I, Fóris G, Páll D, Kosztáczky B, Paragh G Jr, Varga Z, Paragh G: Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia. Metabolism 2005; 54: 1147-1154. (Pubitemid 41206874)
30. Mueller CF, Wassmann K, Widder JD, Wassmann S, Chen CH, Keuler B, Kudin A, Kunz WS, Nickenig G: Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 2008; 117: 2912-2918. (Pubitemid 351787075)
31. Ye Y, Lin Y, Perez-Polo JR, Uretsky BF, Ye Z, Tieu BC, Birnbaum Y: Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008; 181: 3515-3523.
32. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, Huang MH, Uretsky BF, Perez-Polo JR: Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929-935. (Pubitemid 44337136)
33. Silva AR, de Assis EF, Caiado LF, Marathe GK, Bozza MT, McIntyre TM, Zimmerman GA, Prescott SM, Bozza PT, Castro-Faria-Neto HC: Monocyte chemoattractant protein-and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein. J Immunol 2002; 168: 4112-4120.
34. Laaksonen R, Jänis MT, Oresic M: Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology. 2008; 59(2 suppl):65S-68S.